Axovant Alzheimer’s drug fails in trial

Axovant Sciences said on Tuesday its experimental Alzheimer’s drug failed to improve cognitive abilities and daily activities in a late-stage trial, sending its shares plunging 70% in pre-market trading. The drug, intepirdine, was being tested in patients with mild to moderate Alzheimer’s.